Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma
Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma
复制标题
DOI：
10.2169/internalmedicine.47.0595
复制
发表时间：
2008-01-01
影响因子：
1.2
通讯作者：
Lin, Cheng-Wen
中科院分区：
文献类型：
--
作者：
Lin, Chen-Sheng;Chang, Chi-Sen;Lin, Cheng-Wen
目的探讨门冬氨酸氨基转移酶/血小板比值(APRI)、天冬氨酸氨基转移酶/丙氨酸氨基转移酶(AST/ALT)、血小板计数、AST、白蛋白、胆红素、碱性磷酸酶在预测晚期肝纤维化和肝硬变中的作用。结果97例患者中，非乙型、非丙型慢性肝炎9例(9.3%)，慢性乙型肝炎48例(49.5%)，慢性丙型肝炎40例(41.2%)。而AST/ALT或其他血清标志物与进展期肝纤维化和肝硬变显著相关(P
Objective Aspartate aminotransferase-to-platelet ratio index (APRI), aspartate amino transferase-to-alanine aminotransferase (AST/ALT) ratio, platelet count, AST, albumin, bilirubin and alkaline phosphatase were retrospectively evaluated for the prediction of advanced liver fibrosis and cirrhosis in patients with resectable hepatocellular carcinoma in this study.Patients In total, the 97 selected patients consisted of 9 (9.3%) patients with non-B, non-C chronic hepatitis, 48 (49.5%) patients with chronic hepatitis B (CHB) and 40 (41.2%) patients with chronic hepatitis C (CHC).Results The APRI, but not AST/ALT or other serum markers, showed a significant correlation with advanced liver fibrosis and cirrhosis (p